Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesWound CareSummaCare Autologous PRP Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Autologous Platelet-Derived Growth Factors Policy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical necessity for autologous platelet-derived growth factors, including platelet-rich plasma, platelet gel, and related blood-derived products used for wounds and other conditions. Coverage differs by line of business: commercial use is generally considered experimental or unproven, while specified Medicare chronic diabetic wound use may be covered under CMS criteria.

    Policy Summary
    PayerSummaCare
    PolicyAutologous Platelet-Derived Growth Factors Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 13, 2026
    Last ReviewAug 13, 2026
    Next Review DateN/A
    Key ActionFor Medicare coverage, confirm the wound is a chronic non-healing diabetic wound, use an FDA-cleared device indicated for exuding cutaneous wounds, and limit treatment to 20 weeks.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20 weeksMaximum Medicare treatment duration
    30+ daysChronic wound duration threshold
    5Contraindicating conditions
    Medicare

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Plan category covered
    ExperimentalCommercial coverage status

    Coverage Criteria

    Medicare Covered Indication

    CMS covers autologous platelet-rich plasma (PRP) for Medicare services only when ALL of the following criteria are met:

    ALL of the following

    • The service is performed on or after April 13, 2021.
    • Autologous PRP is used to treat a chronic, non-healing diabetic wound.
    • The PRP is prepared using a device whose FDA-cleared indications include management of exuding cutaneous wounds, such as diabetic ulcers.
    • Treatment is provided for a duration not exceeding 20 weeks.<= 20 weeks

    Experimental and Non-Covered Uses

    Coverage is limited to the Medicare indication above. Commercial-member autologous PRP and the uses identified below are experimental, investigational, unproven, or nationally non-covered as specified.

    Apply the applicable exclusion or non-covered-use rule

    • For commercial members, autologous PRP is considered experimental, investigational, or unproven because the effectiveness of these approaches has not been established.

      Commercial-member determination.

    • Nationally non-covered or investigational uses

      • Autologous PDGF for chronic, non-healing cutaneous wounds.
      • Becaplermin, a non-autologous growth factor, for chronic, non-healing subcutaneous wounds.
      • Autologous PRP for acute surgical wounds when applied directly to a closed incision, or for dehiscent wounds.
      • Any other form of autologous platelet-derived growth factor, including use for the conditions listed in this policy, is investigational and experimental.

    Coverage criteria: Autologous platelet-derived growth factor (PDGF) is covered for chronic, non-healing cutaneous wounds. Becaplermin, a non-autologous growth factor, is covered for chronic, non-healing subcutaneous wounds.

    Autologous PRP for acute surgical wounds is not covered when applied directly to a closed incision or when used for dehiscent wounds.

    SummaCare does not cover other forms of autologous platelet-derived growth factors and considers them investigational and experimental for the following conditions and uses: chronic urticaria; alopecia areata (androgenetic alopecia); cervical radiculopathy; lateral epicondylitis; plantar fasciitis; temporomandibular joint (TMJ) dislocation; tendinopathies, including elbow, heel, knee, patella, and shoulder; Achilles tendon ruptures; anterior cruciate ligament surgery; use as adjunctive material to bone graft; avascular necrosis of the hip; cerebral palsy; Crohn's disease-related perianal fistula; gastrocnemius tear; hamstring tear; hip fractures; lumbar facet joint syndrome; osteoarthritis; rotator cuff injuries; urethral stricture; platelet gel application following total knee arthroplasty; platelet-rich plasma combined with stem cells (Regenexx); bone marrow-derived mesenchymal stromal cell administration for Crohn's disease and osteoarthritis; adipose-tissue-derived stem cell injection treatment for chondromalacia patellae; persistent epithelial defects of the cornea; sinus augmentation procedures; Dupuytren's contracture; tonsillectomy; ganglion cyst; osteonecrosis of the jaw; chronic, non-healing cutaneous wounds; becaplermin for chronic, non-healing subcutaneous wounds; and autologous PRP for acute surgical wounds when applied directly to a closed incision or for dehiscent wounds.

    Contraindication: Platelet Dysfunction Syndrome.

    Contraindication: Thrombocytopenia.

    Contraindication: Malignancies or tumors located in the wound.

    Contraindication: Hemodynamic instability.

    Contraindication: Hyperfibrinogenemia.

    For commercial members, SummaCare considers autologous PRP experimental, investigational, or unproven because the effectiveness of these approaches has not been established.

    Autologous platelet-derived growth factor uses outside the CMS-covered indication for chronic, non-healing diabetic wounds are considered investigational. The CMS-covered indication requires treatment of a chronic, non-healing diabetic wound using autologous PRP prepared by a device with FDA-cleared indications that include management of exuding cutaneous wounds, such as diabetic ulcers, and is limited to 20 weeks for services performed on or after April 13, 2021.

    Coding and Coverage Parameters

    Covered HCPCS CodesHCPCSCovered
    G0465Autologous platelet rich plasma (prp) or other blood-derived product for diabetic chronic wounds/ulcers, using an fda-cleared device for this indication
    HCPCS Codes Not CoveredHCPCSNot Covered
    G0460Autologous platelet rich plasma or other blood-derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration and dressings, per treatment
    Chronic wound duration
    Threshold30 days or longer
    Applies toChronic, non-healing cutaneous wounds
    Healing statusThe wound fails to properly complete the healing process
    CMS treatment duration
    Maximum treatment duration20 weeks
    Covered conditionChronic non-healing diabetic wounds
    Device requirement

    Provider and Billing Actions

    Denial Risk

    Commercial Autologous PRP Is Unproven

    For commercial members, SummaCare considers autologous platelet-rich plasma (PRP) experimental, investigational, or unproven because its effectiveness has not been established. Deny or do not authorize coverage for commercial autologous PRP unless an applicable exception is specified.

    Denial Risk

    Non-Covered Wound Indications

    Deny coverage for nationally non-covered wound indications, including autologous platelet-derived growth factor (PDGF) for chronic, non-healing cutaneous wounds; becaplermin for chronic, non-healing subcutaneous wounds; and autologous PRP applied directly to a closed incision for acute surgical wounds or used for dehiscent wounds.

    • Autologous PDGF for chronic, non-healing cutaneous wounds
    • Becaplermin, a non-autologous growth factor, for chronic, non-healing subcutaneous wounds
    • Autologous PRP applied directly to closed incisions for acute surgical wounds or used for dehiscent wounds

    Background

    Autologous platelet-derived growth factors, also called platelet-rich plasma, platelet gel, autologous platelet gel, platelet-rich concentrate, or platelet releasate, are prepared from the patient's own blood. The blood is generally collected by venipuncture, then centrifuged to concentrate platelets and growth factors in a small volume of plasma; platelet-derived factors and fibrin are proposed to support tissue repair and wound healing. A chronic wound has failed to progress through normal healing stages within an expected period, while an acute wound is expected to heal in an orderly and timely manner.

    Definitions

    Autologous platelet-rich plasma (PRP)
    SourceThe patient's own whole blood
    PreparationBlood is collected using a standard peripheral vein puncture and processed using centrifuge techniques
    ConcentrationPlatelets and growth factors are concentrated in a small volume of plasma
    Autologous platelet-derived growth factors
    Also calledPlatelet-rich plasma (PRP), platelet gel, autologous platelet gel, platelet-rich concentrate, or platelet releasate
    Product typeBlood-derived growth factor product
    Preparation
    Policy Summary
    PayerSummaCare
    PolicyAutologous Platelet-Derived Growth Factors Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 13, 2026
    Last ReviewAug 13, 2026
    Next Review DateN/A
    Key ActionFor Medicare coverage, confirm the wound is a chronic non-healing diabetic wound, use an FDA-cleared device indicated for exuding cutaneous wounds, and limit treatment to 20 weeks.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Coverage ParametersProvider and Billing ActionsBackgroundDefinitions

    Contraindication present

    • Platelet Dysfunction Syndrome.
    • Thrombocytopenia.
    • Malignancies or tumors located in the wound.
    • Hemodynamic instability.
    • Hyperfibrinogenemia.
    The PRP must be prepared by a device whose FDA-cleared indications include management of exuding cutaneous wounds, such as diabetic ulcers
    Denial Risk

    CMS Criteria Not Met

    For Medicare claims, authorize autologous PRP for chronic, non-healing diabetic wounds only when every CMS coverage condition is satisfied. Deny coverage when the service is performed before April 13, 2021, exceeds the 20-week duration, is not for a chronic non-healing diabetic wound, or uses a device without FDA-cleared indications that include management of exuding cutaneous wounds such as diabetic ulcers.

    • Covered indication: chronic, non-healing diabetic wounds
    • Service date must be on or after April 13, 2021
    • Coverage duration is limited to 20 weeks
    • Preparation must use a device with FDA-cleared indications for management of exuding cutaneous wounds, such as diabetic ulcers
    Denial Risk

    Contraindications Require Denial or Avoidance

    Do not authorize or provide treatment when a listed contraindication is present; route the case for clinical review or deny the service as appropriate.

    • Platelet Dysfunction Syndrome
    • Thrombocytopenia
    • Malignancy or tumor located in the wound
    • Hemodynamic instability
    • Hyperfibrinogenemia
    Denial Risk

    Other Investigational Uses

    Do not cover other forms or uses of autologous platelet-derived growth factors because SummaCare considers them experimental and investigational. Apply denial guidance to the following uses and related forms.

    • Chronic urticaria; alopecia areata or androgenetic alopecia; cervical radiculopathy; lateral epicondylitis; plantar fasciitis; temporomandibular joint dislocation
    • Tendinopathies involving the elbow, heel, knee, patella, or shoulder; Achilles tendon ruptures; anterior cruciate ligament surgery; adjunctive material to bone graft; avascular necrosis of the hip
    • Cerebral palsy; Crohn's disease-related perianal fistula; gastrocnemius tear; hamstring tear; hip fractures; lumbar facet joint syndrome; osteoarthritis; rotator cuff injuries; urethral stricture
    • Platelet gel application following total knee arthroplasty; PRP combined with stem cells (Regenexx); bone marrow-derived mesenchymal stromal cell administration for Crohn's disease or osteoarthritis
    • Adipose-tissue-derived stem cell injection treatment for chondromalacia patellae; persistent epithelial defects of the cornea; sinus augmentation procedures; Dupuytren's contracture; tonsillectomy; ganglion cyst; osteonecrosis of the jaw
    • Chronic, non-healing cutaneous wounds; becaplermin for chronic, non-healing subcutaneous wounds; and autologous PRP applied to closed incisions for acute surgical wounds or used for dehiscent wounds
    Denial Risk

    Commercial Experimental and Investigational Status

    For commercial lines of business, autologous PRP and other forms of autologous platelet-derived growth factors are considered experimental and investigational unless otherwise specified. Deny coverage for commercial services that lack a stated exception.

    • Applies to all commercial lines of business
    • Coverage status: experimental and investigational
    • Exception: unless otherwise specified
    Platelets and growth factors are concentrated from the patient's blood in a small volume of plasma
    Chronic wound
    DefinitionA wound that has failed to progress through the normal wound-healing stages and repair itself within a sufficient time period
    Normal healing processNormal wound healing has three progressive stages
    Expected courseThe wound does not complete repair within the expected period
    Acute wound
    DefinitionA wound for which the normal healing stages are not yet complete
    Expected courseOrderly and timely wound repair is presumed to occur
    Healing statusThe wound is still progressing through the normal healing process
    Chronic non-healing cutaneous wound
    DefinitionA chronic wound that fails to properly complete the healing process
    Persistence threshold30 days or longer
    Wound typeCutaneous wound
    Autologous PRP
    DefinitionPRP derived from blood from the patient who will ultimately receive the product
    Blood sourceThe patient's own blood
    Preparation contextThe blood is donated by the patient and centrifuged to produce an autologous gel
    Homologous PRP
    DefinitionPRP derived from blood donated by multiple donors
    Blood sourceBlood from multiple donors
    Distinguishing featureUnlike autologous PRP, the product is not derived solely from the recipient's blood